Evolocumab, a PCSK9‐Monoclonal Antibody, Rapidly Reverses Coronary Artery Endothelial Dysfunction in People Living With HIV and People With Dyslipidemia

Evolocumab in HIV-Infected Patients With Dyslipidemia

(2020) Franck Boccara et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

PCSK9 Antibody Alirocumab Attenuates Arterial Wall Inflammation Without Changes in Circulating Inflammatory Markers

(2019) Renate M. Hoogeveen et al.   JACC-Cardiovascular Imaging

Coronary Endothelial Dysfunction Is Associated With Elevated Serum PCSK9 Levels in People With HIV Independent of Low‐Density Lipoprotein Cholesterol

(2018) Thorsten M. Leucker et al.   Journal of the American Heart Association

Disparities in the Quality of Cardiovascular Care Between HIV‐Infected Versus HIV‐Uninfected Adults in the United States: A Cross‐Sectional Study

(2017) Joseph A. Ladapo et al.   Journal of the American Heart Association

Prediction of cardiovascular events with levels of proprotein convertase subtilisin/kexin type 9: A systematic review and meta-analysis

(2016) Charalambos Vlachopoulos et al.   ATHEROSCLEROSIS

Effect of monoclonal antibodies to PCSK9 on high-sensitivity C-reactive protein levels: a meta-analysis of 16 randomized controlled treatment arms

(2016) Amirhossein Sahebkar et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Circulating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Predicts Future Risk of Cardiovascular Events Independently of Established Risk FactorsCLINICAL PERSPECTIVE

(2016) Karin Leander et al.   CIRCULATION

Coronary vasomotor responses to isometric handgrip exercise are primarily mediated by nitric oxide: a noninvasive MRI test of coronary endothelial function

(2015) Allison G. Hays et al.   AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY

Cross-talk between LOX-1 and PCSK9 in vascular tissues

(2015) Zufeng Ding et al.   CARDIOVASCULAR RESEARCH

Plasma proprotein convertase subtilisin/kexin type 9 levels and the risk of first cardiovascular events

(2015) Paul M. Ridker et al.   EUROPEAN HEART JOURNAL

Are PCSK9 Inhibitors the Next Breakthrough in the Cardiovascular Field?

(2015) Robert P. Giugliano et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels

(2011) Nicola Ferri et al.   ATHEROSCLEROSIS

Noninvasive Visualization of Coronary Artery Endothelial Function in Healthy Subjects and in Patients With Coronary Artery Disease

(2010) Allison G. Hays et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY